Twi Pharmaceuticals Inc., of Taipei, Taiwan, said its fully owned subsidiary, Twi Biotechnology Inc., has received the designation of rare disease drug by the Taiwan FDA for use of AC-203 to treat epidermolysis bullosa simplex (EBS), and is eligible for applying for coverage under National Health Insurance Administration. Twi Biotechnology has developed proprietary formulations to be used topically for EBS.